Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433182 | 0.86 | APLNR (0.56) | NMUR2NMUR1APLNROPRM1OPRD1 | |
| SCHEMBL30412382 | 0.85 | OPRM1 (0.54) | RENAPLNRCXCL8OPRM1OPRD1 | |
| SCHEMBL31433370 | 0.85 | CXCL8 (0.57) | CAPN1CTSBCXCL8 | |
| SCHEMBL30158741 | 0.85 | APLNR (0.54) | NMUR2NMUR1APLNRCXCL8OPRM1 | |
| SCHEMBL30512680 | 0.82 | CXCL8 (0.54) | NMUR2NMUR1CXCL8 | |
| SCHEMBL21581733 | 0.81 | OPRM1 (0.53) | OPRM1OPRD1 | |
| SCHEMBL30431027 | 0.80 | OPRM1 (0.61) | NMUR2NMUR1OPRM1OPRD1OPRK1 | |
| SCHEMBL31717953 | 0.79 | NTSR1 (0.56) | RENOPRM1OPRD1 | |
| SCHEMBL31247408 | 0.79 | SLC6A2 (0.55) | NMUR2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL30527820 | 0.79 | SLC6A2 (0.58) | RENNMUR2NMUR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | REN 3452/4885NMUR2 3261/4885NMUR1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.